213831-00-6

Usage

Uses

Used in Pharmaceutical Research:
N-(3-aminophenyl)-2-methylpropanamide is used as a building block in the development of various pharmaceuticals for its potential to contribute to the creation of pharmacologically active compounds.
Used in Organic Synthesis:
In the field of organic synthesis, N-(3-aminophenyl)-2-methylpropanamide is utilized as a reagent, playing a crucial role in the synthesis of new materials and compounds.
Used in Medical Field:
N-(3-aminophenyl)-2-methylpropanamide is used as a precursor in the medical field for its potential to be transformed into compounds with therapeutic properties, contributing to the advancement of treatments for various conditions.
Used in Development of New Materials:
This chemical compound may also have applications in the development of innovative materials, where its unique structure and properties can be leveraged to create novel substances with specific characteristics.

Upstream product

• 5434-53-7 N-(3-nitrophenyl)isobutyramide 

Downstream Products

• 25256-03-5 Cyclopropanecarboxylic acid (3-isobutyrylamino-phenyl)-amide 
• 25256-17-1 N-[3-(2,2-Dichloro-acetylamino)-phenyl]-isobutyramide 
• 25256-06-8 N-(3-Isobutyrylamino-phenyl)-3-methyl-butyramide 
• 25256-27-3 Heptanoic acid (3-isobutyrylamino-phenyl)-amide 
• 25228-44-8 N-(3-Isobutyrylamino-phenyl)-3,3-dimethyl-butyramide 
• 25256-26-2 2-Ethyl-N-(3-isobutyrylamino-phenyl)-butyramide 
• 59517-51-0 2-Methyl-pentanoic acid (3-isobutyrylamino-phenyl)-amide 
• 25256-24-0 2-Bromo-N-(3-isobutyrylamino-phenyl)-2-methyl-propionamide 
• 25256-04-6 N-(3-Isobutyrylamino-phenyl)-acrylamide 
• 59517-37-2 2,2-Dimethyl-pentanoic acid (3-isobutyrylamino-phenyl)-amide 
• 25228-39-1 N-[3-(3-Octyl-ureido)-phenyl]-isobutyramide 
• 25256-22-8 N-(3-Isobutyrylamino-phenyl)-2-methyl-acrylamide 
• 25256-05-7 Pentanoic acid (3-isobutyrylamino-phenyl)-amide 
• 25256-25-1 Hexanoic acid (3-isobutyrylamino-phenyl)-amide 

Relevant academic research and scientific papers

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity

The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.

Metasubstituted thiazolidinones, their manufacture and use as a drug

This invention involves thiazolidinone of general formula (I) and its creation and use as inhibitors of polo like kinase (PLK) for the treatment of various diseases.